Dose-dependent decrease in hepatitis delta virus (HDV) RNA achieved with the oral prenylation inhibitor lonafarnib in a proof-of-concept, randomised, double-blinded, placebo-controlled study in patients with chronic HDV infection

导出原文传递

翻译打印收藏纠错

作者： Koh, C. ^[1] ; Canini, L. ^[2] ; Dahari, H. ^[3] ; Cooper, S. ^[4] ; Cory, D. ^[5] ; Winters, M. A. ^[6] ; Choong, I. ^[7] ; Cotler, S. J. ; Kleiner, D. E. ; Yurdaydin, C. ; Heller, T. ; Glenn, J. S.

作者单位： Calif Pacific Med Ctr, Div Hepatol, San Francisco, CA USA ^[1] Ankara Univ, Sch Med, Dept Gastroenterol, TR-06100 Ankara, Turkey ^[2] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Div Gastroenterol & Hepatol, Stanford, CA 94305 ^[3] NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA ^[4] Eiger Biopharmaceut, New York, NY USA ^[5] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA ^[6] Loyola Univ, Med Ctr, Dept Med, Div Hepatol, New Orleans, LA 70118 USA ^[7]

发布时间 2021-01-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of clinical virology

2015年69卷

247-247页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Dose-dependent decrease in hepatitis delta virus (HDV) RNA achieved with the oral prenylation inhibitor lonafarnib in a proof-of-concept, randomised, double-blinded, placebo-controlled study in patients with chronic HDV infection

Journal of clinical virology

相似文献

Journal of clinical virology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Dose-dependent decrease in hepatitis delta virus (HDV) RNA achieved with the oral prenylation inhibitor lonafarnib in a proof-of-concept, randomised, double-blinded, placebo-controlled study in patients with chronic HDV infection

Journal of clinical virology

相似文献

Journal of clinical virology

相关期刊

检索历史清除